
	Application Number:	10/507,009
	Filing Date:	September 7, 2004
	First Named Inventor:	CONSTANTIN G. IOANNIDES
	Art Unit:	1645
	Examiner Name:	Unknown
Number of Pages in this Submission : _____		Attorney Docket Number: UTSC:711US

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input checked="" type="checkbox"/> Form PTO-1449 <input checked="" type="checkbox"/> References C1-C53 <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts/Requirements <input type="checkbox"/> Declaration(s) _____ <input type="checkbox"/> Copy of Notice of Missing Parts/Requirements	<input type="checkbox"/> Drawings(s) _____ <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Statement under 37 CFR §3.73(b) <input type="checkbox"/> Designation of Patent Practitioners <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below) <input type="checkbox"/> Check in the amount of \$ _____ <input checked="" type="checkbox"/> Authorized to be charged to deposit account if check insufficient or inadvertently omitted Deposit account number: 50-1212/UTSC:711US <input type="checkbox"/> Sequence Statement <input type="checkbox"/> Paper Copy of Sequence Listing <input type="checkbox"/> Computer Readable Form (CRF) <input checked="" type="checkbox"/> Postcard <input type="checkbox"/> _____ <input type="checkbox"/> _____
---	---	---


Remarks:

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Fulbright & Jaworski L.L.P.	Customer Number	32425
Signature			
Printed Name	Monica A. De La Paz	Reg. No.	54,662
Date	April 19, 2006		

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or Printed Name	Monica A. De La Paz	Date	April 19, 2006

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Application of:
Constantin G. Ioannides *et al.*

Serial No.: 10/507,009

Filed: September 7, 2004

For: CONTROLLED MODULATION OF
AMINO ACID SIDE CHAIN LENGTH OF
PEPTIDE ANTIGENS

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: UTSC:711US

**CERTIFICATE OF MAILING
37 C.F.R. 1.8**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

April 19, 2006

Date

MDel
Monica A. De La Paz

INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSC:711US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Monica De La Paz", with a stylized flourish at the end.

Monica A. De La Paz
Reg. No. 54,662
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: April 19, 2006

Form PTO-1449 (modified)

Atty. Docket No.

UTSC:711US

Serial No.

10/507,009

List of Patents and Publications for Applicant's

Applicant

Constantin G. Ioannides *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 7, 2004

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	4,433,092	02/21/84	Nemeth	524	414	09/27/82
	A2	4,554,101	11/19/85	Hopp	260	112.5	01/28/83
	A3	4,631,221	12/23/86	Disselbeck and Stahl	428	166	04/03/85
	A4	4,708,781	11/24/87	Poorten	204	180.9	10/20/86
	A5	5,194,392	03/16/93	Geysen	436	518	06/21/90
	A6	5,480,971	01/02/96	Houghton <i>et al.</i>	530	328	06/09/94
	A7	5,550,214	08/27/96	Eberlein <i>et al.</i>	530	328	02/10/94
	A8	6,075,122	06/13/00	Cheever and Disis	530	350	06/06/95
	A9	6,127,524	10/03/00	Casipit <i>et al.</i>	530	387.3	10/18/96
	A10	6,338,945	01/15/02	Nicolette	435	7.1	12/11/97

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Anderson <i>et al.</i> , "Peptide priming of cytolytic activity to her-2 epitope 369-377 in healthy individuals," <i>Clin. Cancer Res.</i> , 6:4192-4200, 2000.
	C2	Baker <i>et al.</i> , "Conversion of a t cell antagonist into an agonist by repairing a defect in the tcr/peptide/mhc interface: implications for tcr signaling," <i>Immunity</i> , 13:475-484, 2000.
	C3	Berman <i>et al.</i> , "The Protein Data Bank," <i>Nucleic Acids Research</i> , 28:235-242, 2000.
	C4	Broome <i>et al.</i> , "Expression of Bcl-2, Bcl-x, and Bax after T cell activation and IL-2 withdrawal," <i>J Immunol</i> , 155:2311-7, 1995.

25459089.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:711US	Serial No. 10/507,009
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Constantin G. Ioannides <i>et al.</i>	
		Filing Date: September 7, 2004	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C5	Brutlag <i>et al.</i> , "Improved sensitivity of biological sequence database searches," <i>Comput. Appl. Biosci.</i> , 6(3):237-245, 1990.
	C6	Castilleja <i>et al.</i> , "Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope Her-2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex," <i>J. Immunol.</i> , 169(7):3545-3554, 2002.
	C7	Chicz and Urban, "Analysis of mhc-presented peptides: applications in autoimmunity and vaccine development," <i>Immunol. Today</i> , 15:155-160, 1994.
	C8	Chou and Fasman, "Conformational parameters for amino acids in helical, β -sheet, and random coil regions calculated from proteins," <i>Biochemistry</i> , 13(2):211-222, 1974.
	C9	Chou and Fasman, "Prediction of protein conformation," <i>Biochemistry</i> , 13(2):222-245, 1974.
	C10	Ding <i>et al.</i> , "Four α 6-tcr/peptide/hla-a2 structures that generate very different t cell signals are nearly identical," <i>Immunity</i> , 11:45, 1999.
	C11	DiSomma <i>et al.</i> , "TCR engagement regulates differential responsiveness of human memory t cells to fas (cd95)-mediated apoptosis," <i>J. Immunol.</i> , 162:3851, 1999.
	C12	Eberl <i>et al.</i> , "MHC class I H-2Kd-restricted antigenic peptides: additional constraints for the binding motif," <i>Int. Immunol.</i> , 5(11):1489-1492, 1993.
	C13	Falk <i>et al.</i> , "Allele-specific motifs revealed by sequencing of self-peptides eluted from mhc molecules," <i>Nature</i> , 351:290, 1991.
	C14	Fetrow and Bryant, "New programs for protein tertiary structure prediction," <i>Biotechnology</i> , 11(4):479-484, 1993.
	C15	Fisk <i>et al.</i> , "Mass-spectrometric analysis of naturally processed peptides recognized by ovarian tumor-associated cd8 ⁺ ctl," <i>Int. J. Oncol.</i> , 10:159-169, 1997.
	C16	Fisk <i>et al.</i> , "Identification of an immunodominant peptide of her-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic t lymphocyte lines," <i>J. Exp. Med.</i> , 181:2109-2117, 1995.
	C17	Garboczi <i>et al.</i> , "Structure of the complex between human t-cell receptor, viral peptide and hla-a2," <i>Nature</i> , 384:134-141, 1996.
	C18	Geysen <i>et al.</i> , "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid," <i>Proc. Natl. Acad. Sci., USA</i> , 81:3998-4002, 1984.

25459089.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:711US	Serial No. 10/507,009
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Constantin G. Ioannides <i>et al.</i>	
		Filing Date: September 7, 2004	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C19	Gillogly <i>et al.</i> , "Induction of immunity to her-2 by tcr directed variants of the ctl epitope e75," <i>FASEB J.</i> , 14:A147.18, 2000.
	C20	Haskell-Luevano <i>et al.</i> , "β-Methylation of the Phe7 and Trp9 melanotropin side chain pharmacophores affects ligand-receptor interactions and prolonged biological activity," <i>J. Med. Chem.</i> , 40:2740-2749, 1997.
	C21	Hausman <i>et al.</i> , "Peptide recognition by two hla-a2/tax _{11.19} -specific t cell clones in relationship to their mhc/peptide/tcr crystal structures," <i>J. Immunol.</i> , 162:5389, 1999.
	C22	Houghten <i>et al.</i> , "A completely sunthetic toxoid vaccine containing <i>escheichia coli</i> heat-stable toxin and antigenic determinants of the heat-labile toxin b subunit," <i>Infection and Immunity</i> , 48:735-740, 1985.
	C23	Houghten, "General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids," <i>Proc. Natl. Acad. Sci., USA</i> , 82:5131-5135, 1985.
	C24	Hruby <i>et al.</i> , "Topographically designed analogues of [D-Pen, D-Pen5]enkephalin," <i>J. Med. Chem.</i> , 34:1823-1830, 1991.
	C25	Jameson and Wolf, "The antigenic index: a novel algorithm for predicting antigenic determinants," <i>Comput Appl Biosci</i> , 4(1):181-186, 1988.
	C26	Kirchhoff <i>et al.</i> , "TCR-mediated up-regulation of c-flip _{short} correlates with resistance toward cd95-mediated apoptosis by blocking death-inducing signaling complex activity," <i>J. Immunol.</i> , 165:6293, 2000.
	C27	Knutson <i>et al.</i> , "Immunization with a her-2/neu helper peptide vaccine generates her-2/neu cd8 t-cell immunity in cancer patients," <i>J. Clin. Invest.</i> , 107:477, 2001.
	C28	Krammer, "CD95's deadly mission in the immune system," <i>Nature</i> , 407:789-795, 2000.
	C29	Lee <i>et al.</i> , "Identification of activated tumor antigen-reactive cd8 ⁺ cells in healthy individuals," <i>Oncol. Reports</i> , 7:455-466, 2000.
	C30	Lu and Celis, "Use of two predictive algorithms of the world wide web for the identification of tumor-reactive t-cell epitopes," <i>Cancer Res.</i> , 60(18):5223-5227, 2000.
	C31	Madden <i>et al.</i> , "The antigenic identity of peptide-mhc complexes: a comparison of the conformations of five viral peptides presented by hla-a2," <i>Cell</i> , 75:693-708, 1993.

25459089.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:711US	Serial No. 10/507,009
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Constantin G. Ioannides <i>et al.</i>	
		Filing Date: September 7, 2004	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C32	Madden, "The three-dimensional structure of peptide-MHC complexes", <i>Annu Rev Immunol</i> , 13:587-62, 1995.
	C33	Mueller <i>et al.</i> , "Differential regulation of bcl-2 and bcl-x by CD3, CD28, and the IL-2 receptor in cloned CD4+ helper T cells. A model for the long-term survival of memory cells", <i>J Immunol</i> , 156:1764-71, 1996.
	C34	Parker <i>et al.</i> , "Scheme for ranking potential hla-a2 binding peptides based on independent binding of individual peptide side-chains," <i>J. Immunol.</i> , 153:163, 1994.
	C35	Peitsch <i>et al.</i> , "Large-scale protein modelling and integration with the swiss-prot and swiss-2d page databases: the example of <i>escherichia coli</i> ," <i>Electrophoresis</i> , 18:498, 1997.
	C36	Rammensee <i>et al.</i> , "SYFPEITHI: database for mhc ligands and peptide motifs," <i>Immunogenetics</i> , 50:213-219, 1999.
	C37	Rongcun <i>et al.</i> , "Identification of new her2/neu-derived peptide epitopes that can elicit specific ctl against autologous and allogeneic carcinomas and melanomas," <i>J. Immunol.</i> , 163:1037-1044, 1999.
	C38	Roy and Nicholson, "Cross-talk in cell death signaling," <i>J. Exp. Med.</i> , F21-25, 2000.
	C39	Saper <i>et al.</i> , "Refined structure of the human histocompatibility antigen hla-a2 at 2.6 Å resolution," <i>J. Mol. Biol.</i> , 219:277, 1999.
	C40	Simon <i>et al.</i> , "Modeling mhc class II molecules and their bound peptides as expressed at the cell surface," <i>Mol. Immunol.</i> , 38(9):681-687, 2002.
	C41	Spencer and Braciale, "Incomplete cd8+ t lymphocyte differentiation as a mechanism for subdominant cytotoxic t lymphocyte responses to a viral antigen," <i>J Exp Med</i> , 191:1687-1698, 2000.
	C42	Stern and Wily, "Antigenic peptide binding by class I and class II histocompatibility proteins," <i>Structure</i> , 2:245-251, 1994.
	C43	Thomas <i>et al.</i> , "The structure, metabolism and function of the carcinoembryonic antigen gene family," <i>Biochim. Biophys. Acta</i> , 1032:177, 1990.
	C44	Van der Zee <i>et al.</i> , "Efficient mapping and characterization of a t cell epitope by the simultaneous synthesis of multiple peptides," <i>Eur. J. Immunol.</i> , 19:43-47, 1989.

25459089.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. UTSC:711US	Serial No. 10/507,009
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Constantin G. Ioannides <i>et al.</i>	
	Filing Date: September 7, 2004	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C45	Wallace <i>et al.</i> , "Mechanisms of adoptive immunotherapy: improved methods for <i>in vivo</i> tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells," <i>Cancer Res.</i> , 53:2358-2367, 1993.
	C46	Ward <i>et al.</i> , "Oxidant-induced s-glutathiolation inactivates protein kinase c- α (pkc- α): a potential mechanism of pkc isozyme regulation," <i>Biochemistry</i> , 39:10319, 2000.
	C47	Warner <i>et al.</i> , "Induction of HIV-specific ctl and antibody responses in mice using retroviral vector-transduced cells," <i>AIDS Res. and Human Retroviruses</i> , 7:645-655, 1991.
	C48	Weidmann <i>et al.</i> , "Relevance of the t cell receptor for immunotherapy of cancer," <i>Cancer Immunol. Immunother.</i> , 39:1-14, 1994.
	C49	Weinberger <i>et al.</i> , "Identification of human glucocorticoid receptor complementary dna clones by epitope selection," <i>Science</i> , 228:740-742, 1985.
	C50	Williams <i>et al.</i> , "A kinetic threshold between negative and positive selection based on the longevity of the t cell receptor-ligand complex," <i>J. Exp. Med.</i> , 189:1531-1544, 1999.
	C51	Wolf <i>et al.</i> , "An integrated family of amino acid sequence analysis programs," <i>Comput. Appl. Biosci.</i> , 4(1):187-191, 1988.
	C52	Zaks and Rosenberg, "Immunization with a peptide epitope (p369-377) from her-2/neu leads to peptide-specific cytotoxic t lymphocytes that fail to recognize her-2/neu+ tumors," <i>Cancer Res.</i> , 58:4902-4908, 1998.
	C53	zum Buschenfelde <i>et al.</i> , "Generation of tumor-reactive ctl against the tumor-associated antigen her2 using retrovirally transduced dendritic cells derived from cd34 ⁺ hemopoietic progenitor cells," <i>J. Immunol.</i> , 165:4133-4140, 2000.

25459089.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.